Results 101 to 110 of about 1,251,059 (351)
Systemic Therapy in Endometrial Cancer: Recent Advances. [PDF]
Endometrial cancer is a chemosensitive disease. Studies have established a clear benefit of chemotherapy in advanced stages and trials are ongoing to define its role in early stages as well.
Bhise, R+5 more
core +1 more source
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte+10 more
wiley +1 more source
Guidelines for training in medical oncology from the American board of internal medicine [PDF]
openalex +1 more source
Short view of leukemia diagnosis and treatment in Iran [PDF]
Background: Early diagnosis and treatment of leukemia patients remains a fundamental aim in clinical oncology, especially in developing country. Present study highlights the basic requirements of these patients in Iran.
Alizadeh, S.+11 more
core +1 more source
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
American Board of Internal Medicine guidelines for training in hematology and medical oncology [PDF]
openalex +1 more source
Supplementum 265: Abstracts of the Swiss Oncology & Hematology Congress (SOHC), November 16-18, 2022
Swiss Society of Medical Oncology+2 more
doaj +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. [PDF]
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk.
Aalfs, Cora M+99 more
core